Novira Receives $23 Million To Develop New Antivirals
This article was originally published in The Pink Sheet Daily
Executive Summary
Previously supported by angels and seed-stage investors, the Philadelphia-area start-up has turned to 5AM Ventures and Canaan Partners for a Series A round that will support development of HBV and HIV drug candidates.
You may also be interested in...
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services.
In HIV Research, A Race For The Cure Is Back On Track
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.